title: Effects of ipriﬂavone on postmenopausal syndrome and osteoporosis.
abstract: OBJECTIVE
  To investigate the therapeutic effects of ipriflavone on postmenopausal syndrome and osteoporosis in women.
  
  
  METHODS
  A randomized and double-blind study was conducted. Sixty postmenopausal women with osteoporosis were chosen and they were randomly divided into three groups: Treatment group I was given oral compound calcium acid chelate and Vitamin AD guttate; treatment group II was given oral compound calcium acid chelate, Vitamin AD guttate and ipriflavone; Control group was given placebo and compound calcium acid chelate. The postmenopausal syndrome, bone mineral density (BMD), and bone biochemical markers were assessed 6 and 12 months after the treatment.
  
  
  RESULTS
  In treatment group II, hot flush and ostalgia syndromes were dramatically relieved, BMD and serum calcium level increased markedly and alkaline phosphatase, parathyroid hormone and tartrate-resistant acid phosphatase decreased markedly, comparing with treatment group I and control group (p < 0.05).
  
  
  CONCLUSIONS
  Ipriflavone could inhibit bone resorption and promote bone formation. It is an effective drug for the prevention and treatment to menopausal syndrome and osteoporosis. Ipriflavone could be used as a supplement to estrogen replacement treatment.
authors: Department of Obstetrics and Gynecology, Medical School, The Second Afﬁliated Hospital, Xi'an Jiaotong University, Xi'an, China. zhang_xin101@yahoo.com.cn
authors: Xin
authors: X
authors: Zhang
authors: Shao-Wen
authors: SW
authors: Li
authors: Jin-Fang
authors: JF
authors: Wu
authors: Chun-Li
authors: CL
authors: Dong
authors: Cai-Xia
authors: CX
authors: Zheng
authors: Yun-Ping
authors: YP
authors: Zhang
authors: Juan
authors: J
authors: Du
mesh_terms: D000135:Acid Phosphatase / Q000097:blood; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D015519:Bone Density / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects; D002118:Calcium / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000097:blood; D007529:Isoflavones / Q000008:administration & dosage*; D008593:Menopause; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D048789:Phytoestrogens / Q000008:administration & dosage*; D018709:Statistics, Nonparametric; D000071681:Tartrate-Resistant Acid Phosphatase
chemical_list: D007527:Isoenzymes; D007529:Isoflavones; D010281:Parathyroid Hormone; D048789:Phytoestrogens; D010758:Phosphorus; C018986:ipriflavone; D000410:Alanine Transaminase; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; D002118:Calcium